Press Releases

- Record 2021 total revenue of $439 million, up from $47 million for 2020 -- Record full year HEPLISAV-B®net product revenue of $62 million -- Record full

EMERYVILLE, Calif. , Feb. 23, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will

EMERYVILLE, Calif. , Feb. 16, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28,

EMERYVILLE, Calif. , Feb. 2, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 73,250 shares

- Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 - Strong financial position supports investment in long-term growth drivers including pipeline expansion - Initiation of Phase 1 clinical trial of shingles vaccine

EMERYVILLE, Calif. , Jan. 7, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares

EMERYVILLE, Calif. , Jan. 5, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.